Tonghua Dongbao Pharmaceutical 通化东宝
14 significant filings since 31 May 2026: 4 on share pledge, 4 on equity incentive and 4 on pledge released, and 1 other kind. The latest, on 1 Sep 2026: 通化东宝关于调整研发生产系统员工持股计划预留部分受让价格的公告.
自 31 May 2026 起有 14 份重大公告：share pledge 4 份、equity incentive 4 份、pledge released 4 份，另有 1 类。最新一份（1 Sep 2026）：通化东宝关于调整研发生产系统员工持股计划预留部分受让价格的公告。
Price History 价格走势
250 trading days 个交易日 · High 最高 ¥10.11 · Low 最低 ¥7.37The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 28 Apr 2021 | 山西证券 | 刘建宏 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 交银国际证券 | 丁政宁,诸葛乐懿 | Buy 买入 | 12 May 2026 | 1 | 11.20 |
| 西南证券 | 杜向阳,雷瑞 | Unrated | 22 Apr 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。